Antidiabetics: Structural Diversity of Molecules with a Common Aim

Author(s): Jelena B. Popovic-Djordjevic*, Ivana I. Jevtic, Tatjana P. Stanojkovic

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 18 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Diabetes mellitus type 2 (DMT2) is an endocrine disease of global proportions which is currently affecting 1 in 12 adults in the world, with still increasing prevalence. World Health Organization (WHO) declared this worldwide health problem, as an epidemic disease, to be the only non-infectious disease with such categorization. People with DMT2 are at increased risk of various complications and have shorter life expectancy. The main classes of oral antidiabetic drugs accessible today for DMT2 vary in their chemical composition, modes of action, safety profiles and tolerability.

Methods: A systematic search of peer-reviewed scientific literature and public databases has been conducted. We included the most recent relevant research papers and data in respect to the focus of the present review. The quality of retrieved papers was assessed using standard tools.

Results: The review highlights the chemical structural diversity of the molecules that have the common target-DMT2. So-called traditional antidiabetics as well as the newest and the least explored drugs include polypeptides and amino acid derivatives (insulin, glucagon-like peptide 1, dipeptidyl peptidase-IV inhibitors, amylin), sulfonylurea derivatives, benzylthiazolidine- 2,4-diones (peroxisome proliferator activated receptor-γ agonists/glitazones), condensed guanido core (metformin) and sugar-like molecules (α-glucosidase and sodium/ glucose co-transporter 2 inhibitors).

Conclusion: As diabetes becomes a more common disease, interest in new pharmacological targets is on the rise.

Keywords: DMT2, peroxisome proliferator activated receptor-γ agonists, metformin, α-glucosidase inhibitors, glucagon- like peptide 1 analogues, dipeptidyl peptidase-IV inhibitors, amylin analogues, sodium-glucose cotransporter 2 inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 22 May, 2018
Page: [2140 - 2165]
Pages: 26
DOI: 10.2174/0929867325666171205145309
Price: $65

Article Metrics

PDF: 37
PRC: 1